Breaking News

Wellesley Island Border Patrol Agents and the Jefferson County Sheriff’s Office Seized Approximately 150 Pounds of Marijuana Readout of Deputy Secretary of Defense Dr. Kathleen H. Hicks’ Meeting With U.K. Permanent Under Secretary of Defence David Williams News Release – VIDEO CONSUMER ALERT: Google Voice Identity Theft is On the Rise Remarks by Deputy Secretary of Commerce Don Graves at the NetZero World Industry Summit FDA Provides Update on External Evaluation to Strengthen Agency’s Human Foods Program Laredo Sector Border Patrol arrests a sex offender and a gang member Biden-Harris Administration Invests $981 Million to Expand Market Opportunities for Rural Businesses and Entrepreneurs in 47 States, Guam and the U.S. Virgin Islands Federal Reserve Board – Federal Reserve Board announces termination of enforcement action with Industrial Bank of Korea and Industrial Bank of Korea New York Branch

Issued: Friday 28 March 2014, London UK

GlaxoSmithKline (GSK) has acquired full ownership of its Indonesian Consumer Healthcare business in a transaction which also includes the company divesting a non-core brand and a manufacturing facility in the country. 

The transaction is with three connected entities.  GSK Consumer Healthcare Pte. Ltd has paid IDR 465 billion (£24.6 million) to Sarasvati Venture Capital Ltd (SVC) for the 30 per cent of the Indonesian Consumer Healthcare business it did not previously own. GSK has also divested its Insto™ eye drops brand to Pharma Healthcare Pte. Ltd and agreed to divest its manufacturing site at Bogor, Indonesia, to PT Pharma Healthcare for a combined total of IDR 133 billion (£7 million).

David Redfern, GSK Chief Strategy Officer, said: “This transaction is a further example of GSK focusing its business in strategically important growth markets such as Indonesia. It will also simplify operations in the Indonesian business.”

The transaction will complete in two stages.  GSK has completed the purchase of the shares and the divestment of the Insto brand.  The Bogor manufacturing site will transfer to PT Pharma Healthcare in 2015.

GSK’s Indonesian Consumer Healthcare business sells brands such as Panadol™, Sensodyne™ and Scotts™, and is an important emerging markets business for GSK. It has seen significant growth over the last five years, with net sales reaching close to £50 million in 2013 in comparison to around £16 million in 2008. With increased geographical coverage and by using targeted product innovation serving a fast-expanding middle class, the future prospects for the business are strong.

Insto eye drops are manufactured at the Bogor site and the brand is only sold in Indonesia. GSK will continue to sell the same formulation under the brandEyemo™ across a number of other emerging markets, which are unaffected by this transaction.

GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please


Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D ‘Risk factors’ in the company’s Annual Report on Form 20-F for 2013.

Source link